Evaluating quality of life in diabetic patients with chronic Charcot foot
Official title: Factors Associated With Quality of Life Outcomes in Diabetic Patients With Chronic Wound-free Charcot Foot
Run by Centre Hospitalier Universitaire de Nīmes · NCT05491577 · Data updated 2026-11-12
This study looks at how living with chronic Charcot foot affects the quality of life for people with diabetes over two years to see what factors might lead to worse outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Nīmes Academic / other |
| Locations | 17 sites (Boulogne-sur-Mer, Pas-de-Calais and 16 other locations) |
| Status | Recruiting |
| Started | January 23, 2023 |
| Main results expected | July 22, 2027 |
| Study ends | January 22, 2028 |
| Registry record updated | October 23, 2026 |
| Trial ID | NCT05491577 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with Type 1 or Type 2 diabetes who are experiencing chronic osteoarthropathy without foot wounds.
✕Probably not a fit
Patients with non-diabetic osteoarthropathy, acute diabetic osteoarthropathy, or those with foot ulcers will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the evolution of quality of life over two years in patients with chronic Charcot foot, a complication of diabetes. It will involve a multicenter cohort of patients in France, focusing on identifying predictive factors that contribute to deterioration in quality of life. The study will utilize various questionnaires, including the SF-36 and FAAM-F, to gather data on foot and ankle functionality, deformities, and other comorbidities. The goal is to better understand the impact of chronic Charcot foot on patients' lives and identify those at higher risk for poor outcomes.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for diabetic patients suffering from chronic Charcot foot, enhancing their quality of life.
How similar studies have gone: While there is limited data on similar studies, the approach of evaluating quality of life in chronic Charcot foot patients is relatively novel and underexplored.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with Type 1 or 2 diabetes or secondary diabetes * patient hospitalized or consulting for osteoarthropathy in its chronic stage, without wounds * patients affiliated to or beneficiaries of a health insurance scheme. * adult patients (≥18 years old). Exclusion Criteria: * patients with non-diabetic osteoarthropathy of the nerves. * patients with acute diabetic osteoarthropathy of the nerves. * patients with a foot ulcer * patients who have expressed opposition to participating in the study. * patients in an exclusion period determined by another study. * patients under court protection, guardianship or trusteeship. * patients for whom it is impossible to give informed information. * pregnant, parturient, or breastfeeding patients.
Where it's running
-
CHU Bicêtre Service d'Endocrinologie et Maladies de la reproduction 78 rue du Général Leclerc
Le Kremlin-Bicêtre, France Recruiting -
CH de Lens Unité de Diabétologie-Endocrinologie- Nutrition-Obésité Centre Hospitalier Dr SCHAFFNER 99 rte de La Bassée,
Lens, France Recruiting -
CHU de Montpellier Service des Maladies métaboliques 371 av. Doyen Giraud
Montpellier, France Recruiting -
GH Pitié Salpétrière Unité de podologie Service de Diabétologie 47-83 Bd de l'Hôpital
Paris, France Recruiting -
GH Paris Saint Joseph Service de Diabétologie et Endocrinologie 185 rue Raymond Losserand
Paris, France Recruiting -
CHU de Lyon Sud Service d'Endocrinologie-Diabète-Nutrition CH Lyon Sud Pavillon médical, Bat 1B 165 chemin du Grand Revoyet
Pierre-Bénite, France Recruiting
Show 11 more locations
-
CHU Reims Service d'Endocrinologie, diabète-nutrition Rue du Général Koenig
Reims, France Recruiting -
Hôpital DRON Service de diabétologie 135 rue du Président Coty
Tourcoing, France Recruiting -
Centre Hospitalier de Boulogne-sur-Mer
Boulogne-sur-Mer, Pas-de-Calais, France Not yet recruiting -
Groupement Hospitalier Est, Hôpital Cardiologique Service de Diabétologie 28 Av du Doyen Lépine
Bron, France Not yet recruiting -
CH Sud Francilien Service de Diabétologie 40 Avenue Serge Dassault
Corbeil-Essonnes, France Not yet recruiting -
CHU de Grenoble Service d'Endocrinologie Allée des Sablons Les écrins
Grenoble, France Not yet recruiting -
Hôpital Hôtel dieu Service d'Endocrinologie 26 rue d'Harfleur
Le Creusot, France Not yet recruiting -
CHRU de Lille Service d'Endocrinologie Diabétologie et Métabolisme, Hôpital Claude Huriez, Rue Polonovski
Lille, France Not yet recruiting -
CHU de la CONCEPTION Service de Nutrition, Diabétologie, Obésité médicale, chirurgicale 47 Bd Baille
Marseille, France Not yet recruiting -
Hôpital Cochin Service de diabétologie 123 Bd de Port Royal
Paris, France Not yet recruiting -
Hôpitaux Universitaires de Strasbourg Service d'Endocrinologie et Diabétologie 1, place de l'hôpital,
Strasbourg, France Not yet recruiting
Study contacts
- Study coordinator: Sophie Schuldiner, Dr.
- Email: sophie.schuldiner@chu-nimes.fr
- Phone: +33 4.66.68.33.21
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treatment of acute Charcot foot in diabetes patients with Denosumab
This study is testing if Denosumab can help people with diabetes who have acute Charcot foot feel better and recover faster compared to those who get a placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.